| Literature DB >> 35514718 |
Cinzia Bordoni1, Cecilia Maria Cima1, Elisa Azzali2, Gabriele Costantino2, Andrea Brancale1.
Abstract
A microwave enhanced synthesis of prodrug nucleotide (ProTide) analogues is presented. Comparison of conventional thermal heating reaction with microwave irradiation exemplifies the potential of the novel methodology herein presented for the selective 5'-phosphoramidate synthesis, without protection of the 3' position in the ribonucleoside. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35514718 PMCID: PMC9065484 DOI: 10.1039/c9ra01754b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Scheme 15′-ProTide traditional synthetic approaches. Base: adenine, guanine, cytosine, thymine, uracil. X = –OH, –H, Y = –OH, –H. Reagent and conditions: (a) nucleoside, (8) (Z = p-NO2-Ph), t-BuMgCl, solvent, 0–25 °C, 12–48 hours, 10–42% or (b) nucleoside, NMI, (9) (Z = –Cl), solvent, 25 °C, 4–24 hours, 14–39%.
Protected adenosine phosphoramidate (22)–(23)a
|
| ||||||
|---|---|---|---|---|---|---|
| Entry | Reagents | Solvent | Conventional heating (55 °C) | Microwave irradiation* (65 °C) | ||
| Time (min) | Yield** (%) (22) or (23) | Hold time (min)*** | Yield** (%) (22) or (23) | |||
| 1a |
| THF/NMP | 150 | 34 (22) | 2.5 | 41 (22) |
| 2a | 30 | 81 (22) | ||||
| 3a | NMI + (9) | THF/NMP | 120 | 55 (22) | 15 | 28 (22) |
| 4b |
| THF/NMP | 30 | 77 (23) | 2 | 67 (23) |
| 5a | NMI + (19) | THF/NMP | 120 | 55 (22) | 15 | 28 (22) |
| 6a |
| THF/NMP | 15 | 52 (23) | 2 | 36 (23) |
| 7a |
| THF/NMP | 1440 | 29 (22) | 60 | 42 (22) |
| 8a |
| THF/NMP | 480 | 15 (23) | 60 | 28 (23) |
Reaction conditions: (a) compound 17 (1 equivalent), t-BuMgCl (2 equivalent), compound 8 or 18 or 20 or 21 (2 equivalent), solvent (2 mL mmol−1); (b) compound 17 (1 equivalent), NMI (6 equivalent), compound 9 or 19 (2 equivalent), solvent (2 mL mmol−1). For both conditions, ratio THF/NMP is 4.8 : 1. *Microwave PowerMax set at 300 W. Maximum microwave power absorbed by reaction mixture 100 W. **Yields were calculated on the isolated product after automated flash column chromatography purification. ***Hold time reported here does not include 25 s of ramping time to go from 25 °C to target temperature and 50 s to cool down the reaction vessel at 25 °C after MWI.
|
| |||||
|---|---|---|---|---|---|
| Base | Nucleoside | X | Y | 5′-ProTide | 3′,5′-ProTide |
| Adenine | (1) | –OH | –OH | (10) | — |
| Cytosine | (2) | –OH | –OH | (11) | — |
| Cytosine | (3) | –H | –H | (12) | — |
| Guanine | (4) | –OH | –OH | (13) | — |
| Uracil | (5) | –OH | –OH | (14) | — |
| Thymine | (6) | –OH | –OH | (15) | (24) |
| Thymine | (7) | –H | –H | (16) | — |
Reagent and conditions: (a) t-BuMgCl (3 equivalents), (8), solvent (0.1 M. For THF/pyridine or THF/NMP: ratio was 4.8 : 1); (b) NMI (6.3 equivalents), (9), solvent (0.1 M. For THF/pyridine or THF/NMP: ratio was 4.8 : 1). *In this case, 0.5 equivalent of t-BuMgCl were added for 4 times (total of 2 equivalents). **Yield determined as percentage of conversion of the parent nucleoside in the desired mono substituted product and/or undesired bis substituted product by HPLC/UPLC analysis. ***Hold time reported here does not include 25 s of ramping time to go from 25 °C to target temperature and 50 s to cool down the reaction vessel at 25 °C after MWI.
| Entry | Nucleoside | Solvent | Conventional heating (55 °C) | Microwave irradiation | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time (min) | Yield (%)** | Hold time (min)*** | Temperature (°C) | Yield (%)** | |||||||
| Nucleoside | 5′-ProTide | 5′,3′-ProTide | Nucleoside | 5′-ProTide | 5′,3′-ProTide | ||||||
| 1a | (1) | THF/NMP | 60 | 58 (1) | 42 (10) | — | 2 | 65 | 60 (1) | 40 (10) | — |
| 2b | (1) | THF/pyridine | 180 | 45 (1) | 55 (10) | — | 20 | 85 | 38 (1) | 61 (10) | |
| 3a | (2) | DMF | 200 | 48 (2) | 51 (11) | — | 25 | 65 | 19 (2) | 81 (11) | — |
| 4b | (2) | THF/pyridine | 300 | 44 (2) | 55 (11) | — | 25 | 65 | 89 (2) | 11 (11) | — |
| 5a | (3) | DMF | 135 | 1 (3) | 99 (12) | — | 5 | 75 | 19 (3) | 81 (12) | — |
| 6b | (3) | THF | 300 | 47 (3) | 53 (12) | — | 10 | 65 | 10 (3) | 90 (12) | — |
| 7a | (4) | DMF | 450 | 34 (4) | 66 (13) | — | 10 | 75 | 12 (4) | 88 (13) | — |
| 8b | (4) | THF/pyridine | 1440 | 51 (4) | 49 (13) | — | 35 | 65 | 87 (4) | 13 (13) | — |
| 9a | (5) | THF/NMP | 320 | 62 (5) | 38 (14) | — | 15 | 65 | 62 (5) | 38 (14) | — |
| 10b | (5) | THF | 350 | 35 (5) | 65 (14) | — | 35 | 65 | 46 (5) | 54 (14) | — |
| 11a,* | (6) | THF/NMP | 120 | 16 (6) | 45 (15) | 39 (24) | 60 | 65 | 54 (6) | 43 (15) | 3 (24) |
| 12b | (6) | THF | 240 | 13 (6) | 73 (15) | 14 (24) | 5 | 65 | 1 (6) | 70 (15) | 29 (24) |
| 13a | (7) | DMF | 150 | 2 (7) | 98 (16) | — | 1 | 65 | 19 (7) | 81 (16) | — |
| 14b | (7) | THF | 155 | 16 (7) | 84 (16) | — | 3 | 65 | 11 (7) | 89 (16) | — |